Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 30 Recurrence 5 Neoplasms, Plasma Cell 2 Smoldering Multiple Myeloma 1 Neoplasms 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1

Interventions

Rituximab 63 Cyclophosphamide 37 Brentuximab Vedotin 22 Bendamustine Hydrochloride 22 pembrolizumab 20 fludarabine 20 Gemcitabine 20 Doxorubicin 20 Prednisone 19 ibrutinib 17 Vincristine 16 obinutuzumab 14 Lenalidomide 13 Nivolumab 10 Rifampin 8 parsaclisib 7 duvelisib 7 atezolizumab 7 Vorinostat 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 MLN 8237 6 venetoclax 5 ixazomib 5 glofitamab 5 fludarabine phosphate 5 durvalumab 5 acalabrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × elotuzumab × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡